目次

CONTENTS

1 Executive Summary

2 Global Hemodialysis Powder Solution Market
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms

3 Research Methodology
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation

4 Average Pricing Analysis

5 Macro-Economic Indicators

6 Market Dynamics
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends

7 Correlation & Regression Analysis
7.1. Correlation Matrix
7.2. Regression Matrix

8 Recent Development, Policies & Regulatory Landscape

9 Risk Analysis
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis

10 Global Hemodialysis Powder Solution Market Analysis
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological

11 Global Hemodialysis Powder Solution Market
11.1. Market Size & forecast, 2020A-2030F
11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F

12 Global Oncology Pharmaceuticals Market: Market Segmentation
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2. By Type: Market Share (2020-2030F)
12.2.1. Chemotherapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.2. Targeted Therapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.3. Immunotherapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.4. Hormonal Therapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3. By Indication: Market Share (2020-2030F)
12.3.1. Lung Cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.2. Stomach Cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.3. Breast Cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.4. Prostate Cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.5. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4. By End user: Market Share (2020-2030F)
12.4.1. Specialized cancer treatment centers, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.2. Hospitals Pharmacies, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.3. Retail Pharmacies, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F

13 Company Profile
Baxter International Inc.
Fresenius SE & Co. KGaA
Rockwell Medical, Inc.
Farmasol
WEGO Health Co., Ltd.
O.M.A.R S.r.l Pharmaceutical Blister Solution
Renacon Pharma Limited
Melson Medical Corporation Limited
B. Braun
Weigao group
Tom Medical
Gambro
Chief Medical Supplies
Other Prominent Players

14 Consultant Recommendation
**The above given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.